COVID-19: Next virus could be worse, AstraZeneca vaccine creator Sarah Gilbert says
Research that has not been peer reviewed says that Omicron may be more infectious, but not severe
Why the US and its allies are stupid to turn COVID-19 vaccination into a geopolitical power play
The COVID-19 pandemic demands that all nations cooperate to vaccinate the entire global population—a goal that can’t be achieved …
Lateral Thoughts: Mix and match research
We still need to find the best vaccination protocol
Bharat Biotech COVID-19 vaccine claimed to have 80.6% efficacy
'Shot well tolerated in participants; adverse events balanced between vaccine and placebo arms of the trial'
Govt neither denies nor accepts adverse event in Serum Institute COVID-19 vaccine trial
Health secretary claims all procedures followed but refuses to divulge details
COVID-19: How is expiration date of vaccines determined?
Expired vaccines are not particularly unsafe or dangerous, say experts
Oxford COVID vaccine authorised in the UK – global health expert on why this is a key moment
To know the impact of the Oxford vaccine, we’ll have to wait and see. However, amid the intense doom and gloom of 2020, having multiple …
COVID-19 vaccines: Did a delayed second dose give the delta variant an evolutionary helping hand?
Those with a single dose of the Pfizer or AstraZeneca vaccine less-protected than those with 2 doses: Public Health England
India readies for COVID-19 vaccination but vexed questions on the solution remain
The risks the country needs to prepare for, precautions it needs to take, the logistics required and, above all, the implications of it all for …
Serum Institute’s COVID-19 vaccine up for emergency approval
Civil society organisations urge Indian drug regulator to put vaccine trial data in public domain
How Rwanda reached first global COVID-19 vaccination target
Rwanda defined a vaccination plan prior to getting the vaccines
COVID-19: First few peer reviewed studies suggest vaccine induced antibodies fail to protect from Omicron
The studies, published in Nature, covered Oxford-AstraZeneca vaccine, but not India’s indigenous Covaxin
Global COVID-19 cases set to triple with over 3 billion omicron infections in coming 2-3 months: IHME
Australia and New Zealand may experience their worst outbreaks of this pandemic
Vaccines work just fine without side effects says a new Lancet study
Only one in four people experience mild, short-lived systemic side-effects after receiving either the Pfizer Inc or the Oxford University-…
New Delta+ variant found in India can escape antibodies
Mutations in the Delta+ variant can render vaccines and treatments ineffective
Delaying the second COVID-19 vaccine dose: A medical expert answers key questions
The uncertainty is around how long the protective effect of the first dose will last without a second shot
Oxford-AstraZeneca COVID-19 vaccine: What do WHO recommendations say
Health workers at high risk of exposure and older people — including those aged 65 or older — should be given priority for Oxford / …
Everyone DOESN’T need booster jabs of COVID-19 vaccines: Lancet study (but are the rich countries reading?)
Access to vaccination has been vastly inequal; Booster doses in developed countries will further squeeze out low, mid-income …
COVID-19 vaccine update: AstraZeneca vaccinations should continue, benefits outweigh risks, says WHO
Strategic advisory group of experts on immunization called the one-dose Janssen shot as a safe and lifesaving addition to Pfizer, Moderna and …
COVID-19 vaccine update: South Africa may return Serum Institute of India doses
The WHO has approved the Oxford-AstraZeneca coronavirus jab for emergency use. This means the vaccine can be rolled out globally
COVID-19 Vaccine Watch: COVAX has 2 billion doses to supply to 190 countries
End of COVID-19 pandemic in sight with arrival of these vaccines, says WHO
Protection against COVID-19 infection, severe disease falls quickly after AstraZeneca 2nd dose: Lancet
Begins to wane after 18-19 weeks; study stresses on need for booster dose
Effectiveness of COVID-19 vaccines against infection, severe disease declined with new variants; here's how
AstraZeneca vaccine provided least protection against infection, showed most rapid decline
COVID-19 vaccines for all: Decoding global tenders by states
At least a dozen Indian states have floated or will float tenders for procuring vaccines and will also bear the cost
COVID-19: Pfizer, AstraZeneca efficacy significantly reduced against omicron, says UK health agency
Omicron is displaying growth advantage over delta and is poised to become dominant variant in UK